 |
 |
|
 |
||
 |
 |
|
 |
|
|
Last Updated: 10/2/2008
| David F Ransohoff, M.D.
Professor of Medicine |  |
Research Interests
Professor
Cancer Epidemiology, Cancer Prevention and Control
Research Interests
Dr. Ransohoff's primary research interest is in improved methods of colon cancer screening. He has published extensively on the use of colonoscopy screening and surveillance, fecal occult blood testing, sigmoidoscopy, and virtual colonoscopy; his most recent work concerns stool DNA testing, serum proteomics, and the development and assessment of other new 'omics' methods to screen for cancer. Working with NCI's EDRN (Early Detection Research Network) and others, he is leading a multi-center study about serum proteomics to diagnose colon cancer. At UNC he has directed the K30 faculty development program since its inception in 1999, helping train junior faculty build careers in clinical and translational research.
Publications
Publications
Ransohoff DF. Developing molecular biomarkers for cancer. Science 2003; 299:1679-80.
Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med 2003;139:959-65.
Ransohoff DF. Rules of evidence for cancer molecular marker discovery and validation. Nat Rev Cancer 2004; 4: 309-14.
Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF. Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med 2004; 141:264-71.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704-14
Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, Ransohoff DF. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med 2005; 142:86-94.
Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005; 5:142-9.
Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. JNCI 2005;97:315-9.
Ransohoff DF. Colon cancer screening in 2005: status and challenges. Gastroenterology. 2005 May;128(6): 1685-95.
Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60(12):1205-1219.
Ransohoff DF, Martin C, Wiggins WW, Hitt BA, Keku TO, Galanko JA, et al. Assessment of serum proteomics to detect large colon adenomas. Cancer Epidemiol Biomarkers Prev 2008;17: 2188-93.
Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF. Five-year risk of colorectal neoplasia after a negative screening colonoscopy. N Eng J Med 2008;359:1218-24.
E-mail: ransohof@med.unc.edu
Telephone: (919) 966-1256
Address: 4103 Bioinformatics, CB 7080, UNC-CH Chapel Hill, NC 27599-7080
